Incyte (INCY) Expected to Announce Earnings on Tuesday

27 Apr 2026, 07:38 by Jessica Moore · The Cerbat Gem

Incyte (NASDAQ:INCY – Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect Incyte to post earnings of $1.40 per share and revenue of $1.2346 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:00 AM ET.

Incyte (NASDAQ:INCY – Get Free Report) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.35 billion. Incyte had a net margin of 25.03% and a return on equity of 26.34%. The business’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.43 EPS. On average, analysts expect Incyte to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Incyte Stock Performance

Shares of Incyte stock opened at $94.65 on Monday. The firm has a market cap of $18.84 billion, a PE ratio of 14.77, a price-to-earnings-growth ratio of 0.75 and a beta of 0.85. The firm’s 50-day simple moving average is $96.09 and its 200-day simple moving average is $98.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.32. Incyte has a 1 year low of $57.77 and a 1 year high of $112.29.

Insider Activity at Incyte

In other Incyte news, insider Pablo J. Cagnoni sold 18,667 shares of the firm’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $96.50, for a total value of $1,801,365.50. Following the sale, the insider owned 262,692 shares in the company, valued at approximately $25,349,778. This trade represents a 6.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.80% of the company’s stock.

Institutional Investors Weigh In On Incyte

Several large investors have recently made changes to their positions in INCY. Sivia Capital Partners LLC increased its stake in shares of Incyte by 147.9% during the second quarter. Sivia Capital Partners LLC now owns 12,077 shares of the biopharmaceutical company’s stock valued at $822,000 after acquiring an additional 7,206 shares during the period. Birchwood Financial Partners Inc. acquired a new position in shares of Incyte during the fourth quarter valued at approximately $115,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Incyte during the fourth quarter valued at approximately $65,000. Smartleaf Asset Management LLC increased its stake in shares of Incyte by 7.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,628 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 113 shares during the period. Finally, Brown Brothers Harriman & Co. increased its stake in shares of Incyte by 40.2% during the fourth quarter. Brown Brothers Harriman & Co. now owns 1,147 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 329 shares during the period. Institutional investors and hedge funds own 96.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $135.00 target price on shares of Incyte in a research note on Wednesday, April 15th. Wall Street Zen lowered shares of Incyte from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. The Goldman Sachs Group reiterated a “neutral” rating and set a $90.00 price objective on shares of Incyte in a research note on Thursday, January 8th. UBS Group dropped their price objective on shares of Incyte from $104.00 to $94.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 25th. Finally, TD Cowen reiterated a “buy” rating on shares of Incyte in a research note on Tuesday, January 13th. Ten research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Incyte has a consensus rating of “Hold” and a consensus price target of $104.89.

View Our Latest Analysis on INCY

Incyte Company Profile

(Get Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.